Core Insights - Monopar Therapeutics Inc. is presenting new data from the Phase 2 ALXN1840-WD-204 copper balance study at the AASLD conference, highlighting the company's focus on innovative treatments for unmet medical needs [1][2] Study Findings - The oral presentation by Professor Aftab Ala indicates that treatment with ALXN1840 (tiomolybdate choline) resulted in a rapid and sustained improvement in daily copper balance in Wilson disease patients, primarily through increased fecal copper excretion [2] - The mean daily copper balance among patients treated with ALXN1840 (n=8) showed significant improvement compared to pre-treatment baseline, with positive results observed during both the initial 15 mg once-daily dosing period (days 1-28) and the entire treatment duration (days 1-39) [3] Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company with a focus on late-stage ALXN1840 for Wilson disease and various radiopharmaceutical programs, including MNPR-101-Zr for imaging advanced cancers and MNPR-101-Lu and MNPR-101-Ac225 for treating advanced cancers [5]

Core Insights - Monopar Therapeutics Inc. announced the publication of a peer-reviewed Letter to the Editor in the Journal of Hepatology, discussing the effects of ALXN1840 on copper balance in patients with Wilson disease [1][2] Group 1: Study Findings - The earlier conclusion from the Phase 2 ALXN1840-WD-204 study indicated that ALXN1840 did not promote copper excretion due to methodological limitations in the copper balance equation [2] - The new analysis shows that ALXN1840 statistically significantly improved copper balance, increasing copper excretion over the study duration [2] - Key findings include: - For the 15 mg/day treatment period, the mean daily difference in copper balance was -0.367 mg (p=0.005) - For the overall treatment period, the mean daily difference was -0.289 mg (p=0.023) - The cumulative mean change from baseline was -6.08 mg (95% CI: -10.18 mg to -1.98 mg) [5] Group 2: Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs, including late-stage ALXN1840 for Wilson disease [8] - The company also has radiopharmaceutical programs in various stages of development for imaging and treating advanced cancers [8]